All In Biotech

Drug Trial Radar · NCT05166837

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002Following Intravenous Infusion in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jan 10, 2022

Primary completion

Jan 12, 2023

Study completion Jan 12, 2023

Sponsor

Sponsor type
Industry
First posted
Dec 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

Conditions

  • Healthy

Interventions

  • STSA-1002 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

  • STSA-1002 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

  • STSA-1002 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

  • STSA-1002 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

  • STSA-1002 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities.Time frame: 48 days
  2. Maximum plasma concentration (Cmax)Time frame: Up to 1152 hours postdose
  3. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Up to 1152 hours postdose
  4. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Up to 1152 hours postdose
  5. Time of maximum concentration (Tmax)Time frame: Up to 1152 hours postdose
  6. Elimination half-life (t1/2)Time frame: Up to 1152 hours postdose
  7. Elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Up to 1152 hours postdose
  8. Last measurable concentration (Clast)Time frame: Up to 1152 hours postdose
  9. Mean residence time (MRT)Time frame: Up to 1152 hours postdose
  10. Clearance (CL)Time frame: Up to 1152 hours postdose
  11. Apparent volume of distribution (Vz)Time frame: Up to 1152 hours postdose

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The second hospital of Anhui medical university

    Hefei, Anhui, China

  • Peking university People's Hospital

    Beijing, Beijing Municipality, China

  • The fifth affiliated hosipital of Guangzhou medical university

    Guangzhou, Guangdong, China

  • Peking university Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The affiliated hospital of Guizhou medical university

    Guiyang, Guizhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.